Research into NAD-related compounds is exploring measurable effects on human metabolism. In a 10-week randomised, placebo-controlled study, oral nicotinamide mononucleotide (NMN) improved muscle insulin sensitivity in postmenopausal women with prediabetes who were overweight or obese. This is a useful signal for further investigation in that specific group. It does not establish a general anti-ageing effect or a benefit for everyone. Read the clinical trial.
A higher biomarker is not the same as better health
A 2026 systematic review covering studies through October 2025 found that oral NMN and nicotinamide riboside (NR) commonly increased NAD-related biomarkers. They were generally tolerated over the short study periods. However, effects on meaningful metabolic, physical and other health outcomes varied, and many results were null or limited to particular measures. The review concluded that clinical effectiveness for anti-ageing and general wellness remained inconclusive. Read the evidence review.
Keep the formulations separate
NMN and NR are NAD precursors; they are not equivalent to administering NAD+ itself. The review found no eligible clinical-outcome trials of intravenous or intramuscular NAD+ for anti-ageing or wellness. Oral-precursor results therefore cannot substantiate promises for NAD+ pens, injections or drips. Short-term tolerability also does not establish long-term safety. The constructive next step is better clinical research, rather than promises of rejuvenation or guaranteed energy improvements.
Educational summary, not personal medical advice or an endorsement of a supplier or product. No dosing or ordering guidance is provided. This editorial has not been independently medically reviewed. Sources checked 30 October 2026.
A six-month randomised, double-blind, placebo-controlled trial studied oral glutathione in 54 healthy, non-smoking adults. Researchers found increases in glutathione levels in several body compartments, with some measures increasing by around 30–35% in the higher-intake group. The results challenge the blanket claim that oral glutathione can never affect body stores. Read the study, published in the European Journal of Nutrition.
Why the finding is interesting
The trial also reported changes in oxidative-stress measures and an immune-cell laboratory measure. These findings support further study of biological effects. However, the trial was small and its main outcomes were biomarkers. It did not establish fewer infections, longer life or reliable skin-lightening benefits. Glutathione levels returned towards baseline after supplementation stopped. It would be misleading to turn these findings into broad “detox” or disease-prevention promises.
Oral findings do not validate injections
The study tested oral supplementation, not pens, injections or drips. Different routes and formulations require their own evidence. In August 2026, the US FDA warned about adverse events associated with certain compounded intravenous glutathione products made from dietary-supplement-grade material. Reports included serious reactions and hospitalisations linked to possible endotoxin exposure. This was a specific product-quality warning, not proof that every formulation carries identical risk. Read the FDA safety notice.
A useful perspective
The encouraging message is that oral glutathione has measurable human research behind it. The unanswered question is how consistently those biological changes translate into outcomes people can feel or that improve long-term health. Discuss supplement decisions with a qualified healthcare professional.
Educational summary, not personal medical advice or an endorsement of a supplier or product. No dosing or ordering guidance is provided. This editorial has not been independently medically reviewed. Sources checked 30 October 2026.
The SURMOUNT-1 programme offers encouraging evidence for medically supervised treatment. Its original 72-week randomised trial involved 2,539 adults with obesity or overweight and a weight-related complication, without diabetes. It found substantial weight reduction and improvements in measured cardiometabolic risk factors. Gastrointestinal side effects were common, and some participants stopped treatment because of adverse events. Read the original trial.
The longer-term findings
A subsequent analysis followed 1,032 participants who had both obesity and prediabetes. At 176 weeks, average weight reductions across tirzepatide groups ranged from 12.3% to 19.7%, versus 1.3% with placebo. During treatment, type 2 diabetes was diagnosed in 1.3% of tirzepatide participants and 13.3% of placebo participants. This is an encouraging result in a defined study population, not a guarantee of diabetes prevention. The trial was funded by Eli Lilly. Read the longer-term study.
Benefits need appropriate medical care
South African professional information lists Mounjaro as a Schedule 4 medicine. It includes warnings about pancreatitis, gastrointestinal effects and dehydration, and contraindications involving medullary thyroid carcinoma or MEN 2. Animal thyroid-tumour findings do not establish the same effect in humans. A clinician must assess suitability and monitoring. Evidence for a studied medicine does not verify unregistered or privately labelled products with the same ingredient name. Read the SAHPRA-hosted professional information.
Educational summary, not personal medical advice or an endorsement of a supplier or product. No dosing or ordering guidance is provided. This editorial has not been independently medically reviewed. Sources checked 30 October 2026.
A 2023 randomised phase 2 trial enrolled 338 adults with obesity or overweight and a weight-related condition. At 48 weeks, the highest-dose retatrutide group had an average weight reduction of 24.2%, compared with 2.1% with placebo. These group averages were encouraging, but they are not a prediction of any individual’s outcome. The study was funded by Eli Lilly. Read the peer-reviewed trial.
A newer development
On 28 October 2026, Lilly announced topline results from a separate phase 3 trial in adults with type 2 diabetes. It reported greater reductions in blood glucose and body weight with retatrutide than with the studied semaglutide comparator. This was a manufacturer announcement, not a substitute for independent appraisal of a full peer-reviewed report. It also involved a different population from the earlier obesity trial. Read the announcement.
What remains uncertain
Gastrointestinal adverse events were common in the phase 2 trial, and increases in heart rate were observed. Long-term benefits and risks need continued evaluation. Lilly’s October 2026 information still describes retatrutide as investigational and unapproved by regulators. These findings do not establish the identity, purity or safety of products sold under the same name outside clinical trials. Read the development-status information.
Educational summary, not personal medical advice or an endorsement of a supplier or product. No dosing or ordering guidance is provided. This editorial has not been independently medically reviewed. Sources checked 30 October 2026.
Peptides appear in conversations about skin care, weight management, recovery and healthy ageing. Some are ingredients in medicines with established uses; others remain experimental. Understanding that difference is more useful than treating every product labelled “peptide” as equally safe or effective.
This guide explains the 13 substances and blends commonly discussed in this space, what the evidence can support, and which questions to take to a healthcare professional. It is general education, not a prescription, dosing guide or recommendation to buy or inject a product.
Understanding the evidence
Peptides are short chains of amino acids. However, not everything marketed alongside them is a peptide: NAD+ is a coenzyme, phosphatidylcholine is a lipid, deoxycholate is a bile-acid salt, and vitamin B12 is a vitamin. A shared marketing category does not mean a shared mechanism or safety profile.
Laboratory findings can explain how a substance might work. They do not establish that it improves health in people. Human trials must also be interpreted in context: the exact formulation, route, participants, outcomes and follow-up matter. A change in a blood marker is not automatically a meaningful improvement in symptoms or long-term health.
For South African readers, SAHPRA has warned about unregistered peptides promoted for weight loss, muscle growth, anti-ageing and injury recovery. Risks include contamination, infection, hormonal effects and unknown long-term consequences. A “research use only” label is not approval for human treatment. Ask a registered healthcare professional to check the exact product and its lawful access route. Overseas approval does not establish South African registration. [1]
The reference guide
1. Glutathione
Glutathione is a naturally occurring tripeptide involved in antioxidant defence. Its role inside the body does not prove that extra glutathione will detoxify the body, prevent infections or reverse ageing. A small randomised trial found that oral supplementation increased glutathione stores, so it is inaccurate to claim that all oral glutathione is simply destroyed and ineffective. That study did not establish broad clinical benefits. [3]
A subcutaneous injection goes into tissue beneath the skin, not directly into a vein. Injection does not automatically make a treatment safer or more effective. Injectable glutathione for skin lightening has attracted regulatory warnings, and contaminated preparations have caused serious reactions. [4][5]
2. GLOW blends
“GLOW” is a marketing name rather than a standardised medicine. The formulation described here combines BPC-157, TB-500 and GHK-Cu; labels and strengths may vary. Claims that this mixture accelerates healing after cosmetic procedures should not be treated as established clinical benefits. FDA safety concerns about these ingredients also make reassurance about the blend inappropriate. [2]
3. GHK-Cu
GHK-Cu is a copper–peptide complex. Research or experience involving a topical preparation cannot establish the benefits or safety of an injectable version. The FDA identifies limited human safety data for injectable GHK-Cu and possible immune-reaction risks. Pen packaging does not resolve those uncertainties. [2]
4. Ipamorelin
Ipamorelin is studied for its ability to stimulate growth-hormone release. Early research demonstrating selective hormone effects was preclinical, not proof of improved sleep, body composition or healthy ageing in people. The FDA also identifies safety uncertainties for injectable use. [6][2]
5. NAD+
Nicotinamide adenine dinucleotide is a coenzyme involved in cellular metabolism, not a peptide. A 2026 systematic review found that human health outcomes from NAD-related interventions were mixed and identified no eligible outcome trials of intravenous or intramuscular NAD+ itself for anti-ageing or wellness. Raising NAD-related markers should not be presented as proof of longer life, better cognition or improved energy. [7]
The FDA has received reports of severe chills, shaking, vomiting and fatigue following injectable NAD+ products and has warned about unsuitable ingredients and endotoxin contamination. Evidence for oral precursors cannot simply be transferred to injected NAD+. [8]
6. PPC and deoxycholate
Phosphatidylcholine and deoxycholate mixtures are discussed as “fat-dissolving” treatments, but they are not peptides. In the United States, approved deoxycholic acid injections have a specific indication for fat beneath the chin. This does not validate arbitrary PPC mixtures, treatment of other body areas, or weight-loss claims. FDA safety information describes potentially persistent injection-site reactions and warns about unapproved products. South African product status must be checked separately. [9]
7. Retatrutide
Retatrutide targets GIP, GLP-1 and glucagon receptors. Lilly’s October 2026 update describes it as an investigational medicine without regulatory approval. Trials are examining obesity, type 2 diabetes and related conditions. Promising trial findings do not turn an online vial into an approved treatment. [10]
Headline percentages depend on the study population, treatment duration and analysis used. They should not be presented as a guaranteed personal result or as proof that one treatment is superior to another without an appropriate direct comparison.
8. Tirzepatide
Tirzepatide acts at GIP and GLP-1 receptors and is used in prescription medicines. Aspen announced SAHPRA approval of Mounjaro for chronic weight management, alongside dietary and physical-activity measures, effective October 2025; it had previously launched for type 2 diabetes. This registration does not extend automatically to other products carrying the ingredient name. [11]
Clinical assessment remains essential. Prescribing information describes gastrointestinal side effects and warnings involving pancreatitis, gallbladder disease and dehydration-related kidney injury. It also includes contraindications involving medullary thyroid carcinoma and MEN2, plus relevant medicine interactions. A prescriber should use the current local product information and consider pregnancy, medical history and other treatments. Weight loss is variable and is not guaranteed. [12]
9. Wolverine Stack
“Wolverine Stack” usually describes BPC-157 with TB-500. Dramatic claims about repairing tendons, healing bowel disease or preventing reinjury are not established benefits of this combination. FDA concerns include limited safety information and peptide-related impurities; TB-500 should not automatically be equated with all thymosin beta-4 research. [2]
10. CJC-1295 and products labelled no DAC
The exact molecule matters when interpreting a CJC-1295 label. Do not transfer study findings between differently labelled formulations or assume a combination with another peptide is validated. The FDA reports limited clinical data and adverse events including increased heart rate and systemic vasodilation. [2]
11. Kisspeptin-10
Kisspeptin research concerns reproductive hormone signalling and sexual function. A small controlled study in men with low sexual desire used kisspeptin-54 under research supervision, not a retail kisspeptin-10 regimen. Those findings cannot establish claims of improved fertility, testosterone or mood from a different product. [13]
12. PT-141 or bremelanotide
The FDA-approved bremelanotide product, Vyleesi, has a narrow indication: acquired, generalised hypoactive sexual desire disorder in premenopausal women meeting specified criteria. Its label does not indicate use in men or for enhancing sexual performance. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea, blood-pressure effects and skin pigmentation changes are among its concerns. Claims of reliable prolonged arousal or established treatment of male erectile dysfunction go beyond this approval. Local registration must be verified separately. [14]
13. Lipo-C with vitamin B12
“Lipo-C” describes variable mixtures rather than a single standardised peptide medicine. The mixture in this guide includes methionine, inositol, choline and B12, sometimes with other ingredients. B12 deficiency can cause fatigue and warrants appropriate treatment, but NIH guidance states that extra B12 does not improve energy or endurance in people who already obtain enough. This should not be marketed as guaranteed fat loss or a solution to weight-loss plateaus. [15]
Questions to ask before considering treatment
Take the exact product name and ingredient list to a registered doctor or pharmacist. Ask:
What is my diagnosis, and what established alternatives are available?
Is this exact product registered for the proposed use, or is a specific lawful authorisation required?
Does the supporting research involve people, the same formulation and the same route?
What are the likely benefits, uncertainties, side effects and interactions for me?
Who will prescribe, supply and monitor treatment, and what follow-up is needed?
Avoid self-injecting products bought from unverified sources. Seek urgent medical care for breathing difficulty, collapse or severe symptoms following an injection. Suspected adverse reactions can also be reported through SAHPRA’s Med Safety reporting service. [1]
Editorial note: This article was adapted from a supplied reference guide and updated with linked regulatory and research sources on 29 October 2026. It has not been independently medically reviewed. It provides no dosing, mixing or injection instructions and does not endorse experimental products for human use. Regulatory information and evidence can change.